Filing Details

Accession Number:
0001209191-14-002651
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2014-01-09 16:58:03
Reporting Period:
2014-01-06
Filing Date:
2014-01-09
Accepted Time:
2014-01-09 16:58:03
Original Submission Date:
2014-01-09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1371217 Enteromedics Inc ETRM Electromedical & Electrotherapeutic Apparatus (3845) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1134657 Luke Evnin C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-01-06 81,720 $2.50 1,588,033 No 4 S Indirect See footnote
Common Stock Disposition 2014-01-07 190,334 $2.50 1,397,699 No 4 S Indirect See footnote
Common Stock Disposition 2014-01-08 284,531 $2.50 1,113,168 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. Sale of shares pursuant to Rule 10b5-1 Plan adopted on December 4, 2013.
  2. The shares were sold as follows: 68,003 by MPM BioVentures III-QP, L.P. ("BV III QP"), 4,572 by MPM BioVentures III, L.P. ("BV III"), 2,054 by MPM BioVentures III Parallel Fund, L.P. ("BV III PF"), 5,747 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV III KG") and 1,344 by MPM Asset Management Investors 2002 BVIII LLC ("AM LLC").
  3. The shares are held as follows: 1,321,479 by by BV III QP, 88,852 by BV III, 39,924 by BV III PF, 111,670 by BV III KG and 26,108 by AM LLC. MPM BioVentures III GP, L.P. ("BVIII GP") and MPM BioVentures III LLC ("BVIII LLC") are the direct and indirect general partners of BV III QP, BV III, BV III PF and BV III KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM LLC.
  4. The shares were sold as follows: 158,386 by by BV III QP, 10,650 by BV III, 4,785 by BV III PF, 13,384 by BV III KG and 3,129 by AM LLC.
  5. The shares are held as follows: 1,163,093 by by BV III QP, 78,202 by BV III, 35,139 by BV III PF, 98,286 by BV III KG and 22,979 by AM LLC. BVIII GP and BVIII LLC are the direct and indirect general partners of BV III QP, BV III, BV III PF and BV III KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM LLC.
  6. The shares were sold as follows: 236,772 by by BV III QP, 15,919 by BV III, 7,154 by BV III PF, 20,008 by BV III KG and 4,678 by AM LLC.
  7. The price in Column 4 is a weighted average sale price. The prices actually ranged from $2.50 to $2.51. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  8. The shares are held as follows: 926,321 by by BV III QP, 62,283 by BV III, 27,985 by BV III PF, 78,278 by BV III KG and 18,301 by AM LLC. BVIII GP and BVIII LLC are the direct and indirect general partners of BV III QP, BV III, BV III PF and BV III KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM LLC.